SageView Advisory Group LLC Buys 2,873 Shares of Abbott Laboratories $ABT

Key Points

• SageView Advisory Group LLC increased its stake in Abbott Laboratories by 18.6%, acquiring an additional 2,873 shares during the first quarter, bringing its total holdings to 18,294 shares valued at approximately $2.4 million.
• Abbott Laboratories reported quarterly earnings of $1.26 EPS with revenue of $11.14 billion, surpassing analyst expectations, and set FY 2025 guidance of $5.100-$5.200 EPS.
• The company recently announced a quarterly dividend of $0.59 per share with a yield of 1.8%, reflecting a payout ratio of 29.57%.

SageView Advisory Group LLC raised its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 18.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,294 shares of the healthcare product maker's stock after purchasing an additional 2,873 shares during the period. SageView Advisory Group LLC's holdings in Abbott Laboratories were worth $2,427,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Hughes Financial Services LLC bought a new stake in Abbott Laboratories in the 1st quarter worth about $27,000. Abound Financial LLC bought a new stake in Abbott Laboratories in the 1st quarter worth about $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories in the 1st quarter worth about $30,000. JCIC Asset Management Inc. bought a new stake in Abbott Laboratories in the 1st quarter worth about $32,000. Finally, Vision Financial Markets LLC bought a new stake in Abbott Laboratories in the 1st quarter worth about $33,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $132.04 on Wednesday. The company's fifty day moving average price is $130.52 and its 200-day moving average price is $131.36. The firm has a market capitalization of $229.81 billion, a price-to-earnings ratio of 16.55, a PEG ratio of 2.51 and a beta of 0.69. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were issued a dividend of $0.59 per share. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is currently 29.57%.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.46% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ABT shares. Leerink Partners assumed coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective for the company. Royal Bank Of Canada upped their price target on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Mizuho upped their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research note on Wednesday, July 16th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price target for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, Evercore ISI upped their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average target price of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.